Coagulation Factor IX (Recombinant)

DB00100ApprovedProtein Based TherapiesBlood Coagulation FactorsHemostatics

Coagulation Factor IX (Recombinant) is a form of recombinant human coagulation Factor IX used to treat hemophilia B. Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology.

Protein structure of Coagulation Factor IX (Recombinant)
Mechanism
Curator reviewed
Primary indication
For treatment of hemophilia (Christmas disease).Curator reviewed · 4 structured indications
Formula / weight
C2041H3136N558O641S25 · 46548.2 Da
First approval
Canada, 2003 · United States, 1997 · European Union, 2021
Also known as
Coagulation factor IX recombinant human · Coagulation factor IX, recombinant · Factor IX (Recombinant) · nonacog alfa · nonacog gamma
Brand names
  • Benefix
  • Idelvion
  • Ixinity
  • Rixubis

Resolves to

What you can answer from here — as of July 17, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
93Drug interactionsStructured to mechanism, not free text
Sign in
13Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
101Marketed productsAcross 8 countries and 21 labellers
Sign in
34+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Coagulation Factor IX (Recombinant), and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account